Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

ASAPS supports new national registry for breast implants

The American Society for Aesthetic Plastic Surgery (ASAPS) announces today its support of a new national registry for breast implants that will be compiled by the American Society of Plastic Surgeons (ASPS) in collaboration with the Food and Drug Administration (FDA). This registry will document reported cases of a very rare condition, Anaplastic Large Cell Lymphoma (ALCL), in the presence of breast implants.

27 Jan 2011

U.S. FDA announces link between breast implants and ALCL

The U.S. Food and Drug Administration today announced a possible association between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma, a very rare type of cancer.

27 Jan 2011

ASPS, FDA collaborate to establish national breast implant registry

The American Society of Plastic Surgeons (ASPS) is establishing a national registry for breast implants in collaboration with the Food and Drug Administration (FDA). The registry is being developed in response to reports of a rare lymphoma--Anaplastic Large Cell Lymphoma (ALCL)—in a very small number of women with breast implants.

27 Jan 2011

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.

25 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

How genetic abnormalities transform normal cells into leukemic cells

Cancer scientists led by Dr. John Dick at the Ontario Cancer Institute (OCI) and collaborators at St Jude Children's Research Hospital (Memphis) have found that defective genes and the individual leukemia cells that carry them are organized in a more complex way than previously thought.

21 Jan 2011

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinapar™ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

University of Illinois receives Friends of Mel Foundation support grant for Bone Marrow Transplant Program

The University of Illinois is set to receive a grant from the Friends of Mel Foundation (FOM) in support of their Bone Marrow Transplant Program. The program was selected as the recipient of the Mel's Magic award for January 2011. Mel's Magic was created by FOM in May 2009 to familiarize their supporters with other organizations that work tirelessly to make a difference in the cancer community.

14 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Beth Israel Deaconess Medical Center cancer geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient of the 2011 Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

Epigenetic therapy holds promise for cancer management

Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.

12 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics, announced today that it has entered into a collaboration agreement with Pfizer under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

7 Jan 2011

Lymphoma News and Research

Further Reading

ASAPS supports new national registry for breast implants

U.S. FDA announces link between breast implants and ALCL

ASPS, FDA collaborate to establish national breast implant registry

Emergent BioSolutions initiates TRU-016 Phase Ib/II study for chronic lymphocytic leukemia

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

How genetic abnormalities transform normal cells into leukemic cells

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

National Jewish Health issued method patent for desensitizing B cells

University of Illinois receives Friends of Mel Foundation support grant for Bone Marrow Transplant Program

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Epigenetic therapy holds promise for cancer management

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Seattle Genetics enters ADC collaboration agreement with Pfizer

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News